C2N's New Blood Test Combining p-tau217 Ratio with Aβ42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment - Business Wire

Data released from C2N Diagnostics, presented today at the Alzheimer's Association International Conference, demonstrated that a blood test combining

SAN DIEGO--(BUSINESS WIRE)--Data released from C2N Diagnostics, presented today at the Alzheimer's Association International Conference, demonstrated that a blood test combining the A42/40 ratio, a c… [+4002 chars]

full article...